DrugPatentWatch Database Preview

Details for Patent: 7,781,448

« Back to Dashboard

Which drugs does patent 7,781,448 protect, and when does it expire?

Patent 7,781,448 protects SANCTURA XR and is included in one NDA.

This patent has fifteen patent family members in eleven countries.

Summary for Patent: 7,781,448

Title:	Once daily dosage forms of trospium
Abstract:	A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (C.sub.min) and maximum (C.sub.max) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
Inventor(s):	Kidane; Argaw (Montgomery Village, MD), Flanner; Henry H. (Montgomery Village, MD), Bhatt; Padmanabh (Rockville, MD), Raoufinia; Arash (McLean, VA)
Assignee:	Supernus Pharmaceuticals, Inc. (Rockville, MD)
Application Number:	11/889,962
Prior Art and Litigation Support	Order Prior Art and Litigation support for Patent 7,781,448
Patent Claim Types: see list of patent claims	Composition; Dosage form; Formulation; Use;

Drugs Protected by US Patent 7,781,448

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Allergan	SANCTURA XR	trospium chloride	CAPSULE, EXTENDED RELEASE;ORAL	022103-001	Aug 3, 2007		DISCN	Yes	No					Y	METHOD OF TREATING BLADDER DSYFUNCTION WITH ONCE A DAY TROSPIUM SALT FORMULATION

International Family Members for US Patent 7,781,448

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	493981
Australia	2004289223
Canada	2537103
Germany	602004030931